Skip to content
20-F

Annual Report (Foreign)

Cellebrite DI Ltd. CLBT

0001628280-25-013334

← back to feed
Filed
Mar 18, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 11, 2025 239.47M sh
Cash And Equivalents FY 2024 · Dec 31, 2023 $189.52M
Current Liabilities FY 2024 · Dec 31, 2023 $253.82M
Total Liabilities FY 2024 · Dec 31, 2023 $498.67M
Current Assets FY 2024 · Dec 31, 2023 $422.08M
Total Assets FY 2024 · Dec 31, 2023 $532.89M
Shares Diluted FY 2024 · Dec 31, 2022 195.39M sh
Capex FY 2024 · Dec 31, 2022 $6.9M
Operating Cash Flow FY 2024 · Dec 31, 2022 $20.58M
Eps Diluted FY 2024 · Dec 31, 2022 $0.59
Eps Basic FY 2024 · Dec 31, 2022 $0.64
Sga Expense FY 2024 · Dec 31, 2022 $40.85M
Rd Expense FY 2024 · Dec 31, 2022 $80.62M
Net Income FY 2024 · Dec 31, 2022 $120.81M
Operating Income FY 2024 · Dec 31, 2022 $1.04M
Gross Profit FY 2024 · Dec 31, 2022 $219.91M
Cost Of Revenue FY 2024 · Dec 31, 2022 $50.75M
Revenue FY 2024 · Dec 31, 2022 $270.65M
Stockholders Equity FY 2024 · Dec 31, 2021 −$73.35M